VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
VivoSim Labs, INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.16+0.00 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
VivoSim Labs, INC. revenue by segment
By business segment
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | $18.00K | $40.00K | $26.00K | $28.00K | $37.00K | $51.00K | $15.00K | $28.00K | $25.00K | $29.00K | $5.00K | $0 | 100.0% | -51.4% |
| Product Revenue [Member] | – | $0 | $0 | $0 | $0 | $0 | $9.00K | $2.00K | $14.00K | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of VivoSim Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.